Form 4: Monogram Director's Options Cancelled Post-Merger

Monogram Technologies director Paul Riss's stock options were cancelled and converted into cash and contingent value rights following the merger with Zimmer Biomet.

Summary

• Director Paul Riss's 40,000 stock options in Monogram Technologies Inc. were cancelled.
• This cancellation occurred at the effective time of the merger between Monogram Technologies Inc. and Honey Badger Merger Sub, Inc., a wholly owned subsidiary of Zimmer Biomet Holdings, Inc.
• The merger resulted in Monogram Technologies Inc. becoming a wholly owned subsidiary of Zimmer Biomet.
• Outstanding and unexercised options were generally converted into a right to receive a cash payment equal to the excess of $4.04 (the 'Cash Amount') over the option's exercise price, plus one contractual contingent value right (CVR).
• Options with an exercise price equal to or greater than $4.04 but less than $16.41 (the sum of the Cash Amount and maximum CVR consideration) were cancelled and converted into one CVR less the Cash Amount.
• Options with an exercise price greater than $16.41 were cancelled for no consideration.
• Following the transaction, Paul Riss holds 0 derivative securities.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, which is generally positive for the acquired company's shareholders. The conversion of options into cash and CVRs provides value to option holders, though some options were cancelled for no consideration. The overall sentiment is neutral to positive as it signifies a completed strategic event.

Positives

• The merger with Zimmer Biomet Holdings, Inc. has been consummated, indicating a successful acquisition for Monogram Technologies shareholders.
• Option holders, including Director Paul Riss, received consideration (cash and/or CVRs) for their cancelled options, unless the exercise price was too high.

Negatives

• Director Paul Riss no longer holds any derivative securities in Monogram Technologies Inc.
• Options with an exercise price greater than $16.41 were cancelled for no consideration, potentially resulting in a loss for some option holders.

Risks

• The value of the Contingent Value Rights (CVRs) is subject to future performance or specific milestones, introducing uncertainty for recipients.
• Option holders whose exercise price exceeded $16.41 received no consideration, indicating a potential loss on those specific options.

Future Outlook

The filing primarily reports a past event (merger completion and option cancellation) and does not provide forward-looking statements or guidance for Monogram Technologies Inc. as it is now a wholly-owned subsidiary. The future value of CVRs is contingent on specific terms outlined in the CVR agreement.

Industry Context

This filing reflects a common outcome in corporate mergers and acquisitions where outstanding equity awards of the acquired company are converted or cancelled according to the merger agreement. Zimmer Biomet, a major player in the medical device industry, has expanded its portfolio by acquiring Monogram Technologies.

Comparison to Industry Standards

• The conversion of stock options into cash and/or contingent value rights is a standard practice in M&A transactions, particularly when the acquired company becomes a private entity or a subsidiary.
• The use of CVRs is a mechanism often employed to bridge valuation gaps or provide additional consideration tied to future performance milestones, common in biotech and medical device acquisitions.

Stakeholder Impact

• Shareholders (Monogram Technologies): Their shares were acquired by Zimmer Biomet, likely for cash and/or CVRs, as per the merger agreement.
• Option Holders (Monogram Technologies): Received cash and/or CVRs for their options, or had them cancelled for no consideration, depending on the exercise price.
• Zimmer Biomet: Successfully acquired Monogram Technologies, expanding its business.

Next Steps

• Recipients of CVRs will monitor the conditions and milestones related to the CVR agreement for potential future payouts.

Key Dates

Keywords

Monogram Technologies, MGRM, Zimmer Biomet, Merger, Acquisition, Stock Options, Form 4, Director, Paul Riss, Contingent Value Right, CVR